# MET dependency and drugs in one query

> MET dependency and drugs in one query: DepMap Chronos, ChEMBL potency, Open Targets, CIViC, TCGA and Reactome read together, with data as of 2026-11-06.

Data as of 2026-11-06 · Published 2026-11-08 · Updated 2026-11-06 · https://bioq.bio/blog/en/gene-met-profile

![BioQ result page for the query MET showing CRISPR dependency, drug, disease evidence and expression blocks, each labelled with its source.](https://bioq.bio/blog/img/gene-met-profile/en/hero.webp)

MET is a dependency in 36 of 1178 DepMap cell lines (3.1%) and is not flagged as common essential, so the signal sits in specific lineages rather than everywhere. CNS/Brain stands out with 17 of 90 lines dependent. The layers also list 46 drugs for the gene, and Open Targets ranks papillary renal cell carcinoma highest (score 0.834). All figures are as of 2026-11-06.

## What we asked

We ran one query, MET, and asked what the combined layers say about this receptor tyrosine kinase today. The questions were: how often does knocking it out reduce viability, which drugs are known and how strong are they, which diseases carry the evidence, and how do expression, pathways and interaction partners fit that picture?

The answer is meant as a starting map. A target page like this does not tell you whether MET is a good bet in your model. It tells you where to look and where the layers disagree.

## What BioQ returned for MET dependency and drugs

The query reached 7 distinct resources through 7 engine queries, in 0.74 engine seconds in total. Each block below names its source and release.

**Dependency (DepMap Chronos, release depmap_24q4).** The mean gene effect across all 1178 lines is -0.138, and a more negative value means a stronger loss of viability after knockout. The table shows the eight lineages with the most negative mean effect.

| Lineage | Cell lines | Dependent | % dependent | Mean gene effect |
|---|---|---|---|---|
| CNS/Brain | 90 | 17 | 18.9 | -0.266 |
| Soft Tissue | 45 | 4 | 8.9 | -0.22 |
| Testis | 5 | 0 | 0 | -0.187 |
| Esophagus/Stomach | 69 | 4 | 5.8 | -0.177 |
| Pleura | 21 | 0 | 0 | -0.154 |
| Bone | 46 | 0 | 0 | -0.151 |
| Lung | 126 | 7 | 5.6 | -0.15 |
| Myeloid | 42 | 0 | 0 | -0.148 |

![DepMap Chronos block for MET in BioQ listing dependent cell lines by lineage, with CNS/Brain at the top](https://bioq.bio/blog/img/gene-met-profile/en/dep.webp)
*CRISPR dependency of MET by lineage, as returned for the query MET.*

**Drugs (Open Targets, ChEMBL, Drug Repurposing Hub, ClinicalTrials.gov).** BioQ found 46 drugs for MET and shows 8. The potency column is the best exact pChEMBL value, which is -log10 of the molar potency, so higher is stronger.

| Drug | Max clinical stage | Mechanism | Best exact pChEMBL | Type | Trials by name |
|---|---|---|---|---|---|
| Capmatinib | APPROVAL | Hepatocyte growth factor receptor inhibitor | 9.89 | IC50 | 30 |
| Crizotinib | APPROVAL | Hepatocyte growth factor receptor inhibitor | 9.7 | KD | 94 |
| Tepotinib | APPROVAL | Hepatocyte growth factor receptor inhibitor | 9.05 | IC50 | 23 |
| Cabozantinib | APPROVAL | Hepatocyte growth factor receptor inhibitor | 8.89 | IC50 | 187 |
| Cabozantinib S-Malate | APPROVAL | Hepatocyte growth factor receptor inhibitor | 8.49 | IC50 | 39 |
| Alectinib | APPROVAL | — | — | — | 62 |
| Amivantamab | APPROVAL | Hepatocyte growth factor receptor inhibitor | — | — | 37 |
| Capmatinib Hydrochloride | APPROVAL | Hepatocyte growth factor receptor inhibitor | — | — | 0 |

**Disease evidence (Open Targets).** MET has associations with 2277 diseases. The top six are below, with scores from 0 to 1.

| Disease | Association score | Evidence items |
|---|---|---|
| papillary renal cell carcinoma | 0.834 | 1120 |
| hereditary papillary renal cell carcinoma | 0.768 | 63 |
| hepatocellular carcinoma | 0.759 | 1688 |
| renal cell carcinoma | 0.729 | 3714 |
| non-small cell lung carcinoma | 0.724 | 3636 |
| neoplasm | 0.631 | 7703 |

Three further layers complete the picture:

- **CIViC** holds 41 clinical evidence records for MET variants. Examples include MET Amplification in Lung Non-small Cell Carcinoma with Crizotinib (level C, Sensitivity/Response) and MET Exon 14 Skipping Mutation with Crizotinib (level D, Sensitivity/Response). Foretinib in Papillary Renal Cell Carcinoma for a MET Mutation is level B. MET Amplification with Gefitinib is recorded as Resistance at level D.
- **TCGA/GTEx (Toil recompute)** has 24 cancer types with both tumour and normal samples. Kidney Papillary Cell Carcinoma has a mean tumour value of 14.11 against 11.98 in normal tissue (log2 fold 0.23). Breast Invasive Carcinoma (-0.34) and Glioblastoma Multiforme (-0.35) go the other way.
- **Reactome and STRING** list 44 pathways and 2556 interaction partners. The most specific pathway is Drug-mediated inhibition of MET activation. The top STRING partners are HGF, CBL and GRB2 at a combined score of 999, followed by EGFR at 996.

## What it means and how to read it

Three facts are worth reading before the rest.

**1. Dependency is selective, not general.** Only 3.1% of lines depend on MET, and common_essential is false. By lineage, CNS/Brain has 18.9% dependent lines with a mean effect of -0.266, and Soft Tissue has 8.9%. Lung has 7 of 126 lines (5.6%), and Esophagus/Stomach has 4 of 69. Testis, Pleura, Bone and Myeloid have no dependent lines in this table, though some of them have only a handful of lines in the dataset (Testis has 5). If your model is not in a lineage with a dependent subset, the pan-cell-line average will not describe it.

**2. Potency and trial volume measure different things.** Capmatinib has the highest exact pChEMBL (9.89, IC50), followed by crizotinib at 9.7, which is a KD value and not an IC50. Mixing assay types in one ranking needs care. Cabozantinib has the most trials by name (187), but "trials by name" is a text match on the drug name, not a count of MET-directed studies. Cabozantinib acts on several kinases, and crizotinib on more than MET. Capmatinib Hydrochloride shows 0 trials only because the salt name is rarely used in trial records.

**3. Disease evidence and dependency do not point to the same tissue.** Open Targets puts papillary renal cell carcinoma, hereditary papillary renal cell carcinoma and hepatocellular carcinoma at the top. In TCGA, papillary kidney tumours do express more MET than normal tissue. Yet the eight lineages shown in the DepMap table do not include kidney, and the strongest dependency fraction is in CNS/Brain. There, tumour expression in glioblastoma is lower than in the five normal samples. Association scores integrate genetics, literature and other evidence, so they can be high without a CRISPR dependency in cell lines. Only the top eight lineages are returned, so this table cannot show that kidney lines lack dependency.

The CIViC rows add a clinical angle. Evidence levels run from A (strongest) to E, and the MET rows shown here are B to D, with one resistance association. That is a different statement from a high potency value in a biochemical assay.

Alectinib is listed at the approval stage for MET, with no mechanism and no potency value in this table. The data do not say why. Treat it as a reason to open the source record, not as a MET-directed finding.

## How to reproduce it in BioQ

1. Open BioQ and enter the gene symbol exactly as below.
2. Run the query and wait for the blocks to load. The engine time for the run described here was 0.74 seconds.
3. Read the DepMap block first and note which lineages carry dependent lines.
4. Compare the drug block with the Open Targets and CIViC blocks, and check the assay type next to each pChEMBL value.
5. Open the source named under each block to confirm the record before you use it.

```text
MET
```

[Open this query in BioQ](https://bioq.bio/login?next=%2Fapp%23q%3DMET)

The same question done by hand means querying DepMap, ChEMBL, Open Targets, ClinicalTrials.gov, CIViC, TCGA/GTEx, Reactome and STRING separately, then matching gene identifiers and release versions yourself. BioQ draws on 7 distinct resources in one pass and keeps the source name on every answer. We have not timed the manual route, so we make no claim about it.

## Limits: what the data do not show

- A Chronos gene effect comes from cell lines in culture. It does not show tumour dependency in patients, and the dependency cut-off is a named constant, not a property of the biology.
- Lineage rows with few lines, such as Testis with 5, cannot support a conclusion on their own.
- pChEMBL values mix assay types (IC50, KD) and come from different laboratories. They are not a head-to-head comparison and say nothing about selectivity or tolerability.
- Trial counts are name matches. They do not show indication, outcome or whether MET was the intended target.
- TCGA tumour and normal comparisons have uneven sample sizes, for example 5 normals in glioblastoma against 1092 tumours and 113 normals in breast carcinoma.
- Open Targets scores rank evidence strength for an association. They do not give effect size or causality.
- CIViC records are curated and may be few per variant. A level D entry is preliminary evidence.
- Nothing here is medical advice or a recommendation for treatment.

## Data and method
The numbers on this page were read from the BioQ engine on 2026-11-06 (7 queries, 0.7 s of engine time in total). The tables are generated by code from the engine's answers; the text only restates them.

`/civic`, `/depmap`, `/drugs`, `/interaction`, `/ot_association`, `/pathway`, `/tcga`

Run the same query yourself: [MET](https://bioq.bio/login?next=%2Fapp%23q%3DMET)

*For research use only. This page summarises public data and is not medical advice.*

BioQ is an AI search engine and agent with one goal: making biology research 100X faster. Ask in the web app, over the REST API, or from Claude, ChatGPT or Cursor through MCP.

## Queries used

- [`MET`](https://bioq.bio/login?next=%2Fapp%23q%3DMET)

## Frequently asked questions

### How many cell lines depend on MET in DepMap?

In DepMap (release depmap_24q4), 36 of 1178 cell lines are dependent on MET, which is 3.1%. MET is not flagged as common essential, and the mean Chronos gene effect is -0.138.

### Which lineage shows the strongest MET CRISPR dependency?

CNS/Brain has the highest share in the returned table, with 17 of 90 lines dependent (18.9%) and a mean gene effect of -0.266. Soft Tissue follows with 4 of 45 lines (8.9%).

### Which MET inhibitor has the highest potency in ChEMBL?

Among the eight drugs shown, capmatinib has the highest exact pChEMBL at 9.89 (IC50), then crizotinib at 9.7 (a KD value) and tepotinib at 9.05 (IC50). BioQ found 46 drugs for MET in total, and assay types differ between rows.

### Which diseases does Open Targets associate most strongly with MET?

Papillary renal cell carcinoma ranks highest with a score of 0.834 and 1120 evidence items. Hereditary papillary renal cell carcinoma (0.768) and hepatocellular carcinoma (0.759) follow, out of 2277 associated diseases.

### What MET variant evidence does CIViC hold?

CIViC returns 41 records for MET. Examples include MET Amplification in lung non-small cell carcinoma with Crizotinib (level C, Sensitivity/Response) and MET Exon 14 Skipping Mutation with Crizotinib (level D, Sensitivity/Response).

## Sources

- Dataset: [DepMap CRISPR Chronos gene effect (24Q4)](https://depmap.org/portal/)
- Dataset: [Open Targets Platform; ChEMBL; Drug Repurposing Hub](https://platform.opentargets.org/)
- Dataset: [TCGA pan-cancer expression (UCSC Xena Toil recompute)](https://xenabrowser.net/)
- Dataset: [CIViC: Clinical Interpretation of Variants in Cancer](https://civicdb.org/)
- Dataset: [Reactome pathway knowledgebase](https://reactome.org/)
- Dataset: [STRING v12 protein-protein interactions](https://string-db.org/)

> Results come from public databases as of the date shown and may change. BioQ gives research information, not medical advice.
